Regulation of Gluconeogenesis and Glycogen Metabolism
Two Routes That Lose Capacity in Culture
| Route | Physiological role | Behaviour in culture |
|---|---|---|
| Gluconeogenesis | Glucose synthesis from lactate, glycerol, amino acids | Lost progressively in hepatocytes; absent in most immortalised lines |
| Glycogenesis and glycogenolysis | Glucose storage and mobilisation | Retained in some lines; often low and unmeasured |
Important distinction. Expression of PEPCK and G6PC is necessary for gluconeogenesis and not sufficient for it. A line can transcribe both enzymes and produce no net glucose, because the substrate supply, the mitochondrial oxaloacetate export route and the redox balance are all required. Regulatory claims built on enzyme expression alone are the most common weakness in this literature.
The same applies to glycogen: content is a balance of synthesis and degradation, and it can be constant while both rates are high.
Part 1 — Demonstrating That Gluconeogenesis Is Active
Three designs, in increasing strength.
| Design | What it shows | Requirement |
|---|---|---|
| Glucose release into glucose-free medium | Net production of glucose | No glucose in the medium; no serum glucose; a substrate (lactate, pyruvate, glycerol, amino acids) supplied |
| ¹³C substrate to ¹³C glucose | Carbon from a non-glucose substrate entering glucose | Tracer at a defined concentration; isotopologue analysis of glucose; correction for glycogen contribution |
| Both, with a pathway inhibitor or enzyme knockdown | That the release depends on the gluconeogenic route | A specific perturbation with a rescue |
Readout note. Glucose release measured without removing glucose from the medium measures nothing. Serum contains glucose, phenol-red-free formulations vary, and glycogen breakdown can supply glucose in the absence of gluconeogenesis. The minimum design is glucose-free, serum-free (or dialysed) medium, a defined substrate, and a matched no-substrate control.
The third design is what makes the claim regulatory rather than descriptive. A knockdown of PC, PEPCK or G6PC that reduces glucose release, with a substrate-independent rescue, is a requirement claim; a change in their mRNA is not.
Part 2 — Model Choice for Gluconeogenic Work
| Model | Retains gluconeogenesis | Practical note |
|---|---|---|
| Primary human hepatocytes | Yes, for days | Dedifferentiate rapidly; 3D or sandwich culture extends the window |
| Primary mouse hepatocytes | Yes, short window | Same limitation; isolation stress affects the first day |
| HepG2, Huh7 | Minimal to none | Frequently used and inappropriate for flux claims |
| iPSC-derived hepatocytes | Variable, often low | Requires demonstration in each differentiation batch |
| Renal proximal tubule cells | Yes, in some preparations | Underused; also dedifferentiate |
Caveat on hepatocyte dedifferentiation. The loss is not only transcriptional: mitochondrial function, transporter expression and medium composition all change. A gluconeogenesis experiment in hepatocytes beyond the first few days is usually measuring the culture system rather than the biology, unless the culture format has been validated for the route.
A practical approach that avoids most of this: perform the flux experiment within the validated window, and treat regulatory manipulations that require longer culture as a separate question with its own validation.
Part 3 — Glycogen: Content, Flux and the Distinction
| Measurement | What it reports | Limitation |
|---|---|---|
| Glycogen content (acid hydrolysis + glucose assay) | Standing amount | Cannot distinguish synthesis from degradation |
| Glycogen labelling from ¹³C-glucose | Synthesis over the labelling window | Depends on glucose uptake and on pool size |
| Labelling washout into unlabelled medium | Degradation | Requires a pre-labelling step and a defined chase |
| Glycogen synthase or phosphorylase perturbation | Requirement for the enzymes | Compensation; growth effects |
| PAS staining | Distribution and abundance | Not quantitative without careful controls |
Important distinction. A regulatory claim about glycogen is usually one of three: synthesis rate changed, degradation rate changed, or content changed. The third is compatible with either of the first two and with none of them changing.
The strongest design is a paired one: label incorporation (synthesis) plus washout (degradation) in the same model, with content measured at both ends. Where only content is feasible, the claim should be stated as a content claim.
Part 4 — Regulatory Claims and Their Evidence
| Claim | Minimum evidence | What does not count |
|---|---|---|
| "Hormone or nutrient X increases gluconeogenesis" | Glucose release from a defined substrate, with dose–response and an enzyme-level requirement | PEPCK/G6PC mRNA |
| "X regulates glycogen synthesis" | Label incorporation into glycogen, with a synthase perturbation | Glycogen content |
| "X causes glycogen accumulation" | Content plus labelling or degradation data to show which rate changed | PAS staining alone |
| "The model is gluconeogenic" | Glucose release with a substrate, or ¹³C incorporation into glucose | Enzyme expression; a hepatocyte name |
The first row's dose–response requirement is not a formality: several gluconeogenic regulators act biphasically, and a single concentration can produce the opposite of the effect at a different dose.
Part 5 — Insulin, Glucagon and the Signalling Layer
The classical regulators act through signalling that changes both transcription and acute enzyme activity, and the two timescales are different experiments.
- • Acute regulation (minutes): phosphorylation of glycogen synthase and phosphorylase; allosteric effects; substrate supply. Measured by enzyme activity ratios and by flux over short windows.
- • Transcriptional regulation (hours): PEPCK, G6PC, glucokinase. Measured by mRNA and protein, and only interpretable as flux if a flux measurement accompanies it.
A study that treats a transcriptional change as evidence of a flux change has measured the slower arm and reported the faster one. The opposite error is also common: a 30-minute flux change attributed to transcription.
Part 6 — Model Requirements and Recurring Failures
| Requirement | Why |
|---|---|
| Glucose-free, low-serum medium for release assays | Otherwise the measurement includes medium glucose |
| Substrate defined and matched control without it | Separates gluconeogenesis from glycogenolysis |
| Culture window validated for the route | Dedifferentiation changes capacity |
| Glycogen measured alongside glucose release | The release may be glycogen-derived |
| Substrate concentration documented | Flux depends on precursor supply |
| Timecourse for the flux measurement | Acute and transcriptional effects differ in timing |
Recurring failures:
- • Enzyme expression reported as gluconeogenic capacity in a line that cannot perform it.
- • Glucose release measured in glucose-containing medium.
- • Glycogen-derived glucose attributed to gluconeogenesis, because glycogen was not measured.
- • Hepatoma lines used for gluconeogenesis claims without demonstration.
- • Glycogen content reported as a flux.
- • Single timepoint used to distinguish acute from transcriptional regulation.
- • Insulin or glucagon dose not titrated, in a system where the response is biphasic.
Part 7 — Where This Article Connects
These two routes are the storage and synthesis arms of the pillar's glucose module, and they compete with glycolysis and the PPP for the same glucose-6-phosphate pool. The PPP article in this cluster covers the third branch; the glycogen assay article covers the measurement in more detail; and the tracing articles cover the isotope designs that make carbon attribution possible.
If you need gluconeogenic or glycogen flux demonstrated before it is regulated, we can scope the design with you.
Contact EDITGENE to request a project consultation or quote.
Scientific scope and validation note
Gluconeogenic and glycogenic capacity vary widely between species, cell types and culture formats, and decline with time in culture. The designs here describe how to demonstrate the route, not which model retains it.
Enzyme expression does not establish pathway activity, and glycogen content does not establish either synthesis or degradation rate.
Scientific interpretation and experimental design
- • Demonstrate the route before regulating it. Expression is not activity.
- • Remove glucose from the medium. Otherwise the release assay measures the medium.
- • Measure glycogen when measuring glucose release. Otherwise the source is ambiguous.
- • Content is not flux. Pair labelling with washout.
- • Respect the culture window. Dedifferentiation is fast and not only transcriptional.
- • Separate acute from transcriptional regulation by timing.
Selected references for further reading
- • Adeva-Andany MM, et al. Liver glucose metabolism in humans. Bioscience Reports. 2016;36:e00416.
- • Rui L. Energy metabolism in the liver. Comprehensive Physiology. 2014;4:177–197.
- • Raja V, Natarajan S, Singh A. Glycogen metabolism and its role in growth and development. Journal of Biosciences. 2023;48:32.
- • Sun RC, Denko NC. Quantitative analysis of glycogen metabolism in cultured cells. Methods in Enzymology. 2020;629:1–24.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| PBRM1 Knockout A-549 Cell Line | EDJ0001-K01 | Human | 55193 | Details Get a Quote |
| YTHDC1 Knockout A-549 Cell Line | EDC07652 | Human | 91746 | Details Get a Quote |
| TP53 Knockout HCT 116 Cell Line | EDC07854 | Human | 7157 | Details Get a Quote |
| Sirt2 Knockout MH-S Cell Line | EDJ-KQ78173 | Mouse | 64383 | Details Get a Quote |
| TFE3 Knockout KGN Cell Line | EDJ-KQ48 | Human | 7030 | Details Get a Quote |
| Stub1 Knockout MB49 Cell Line | EDJ-KQ53 | Mouse | 56424 | Details Get a Quote |
| ARID1A Knockout SNK-6 Cell Line | EDJ-KQ64 | Human | 8289 | Details Get a Quote |
| Tet1 Knockout Kupffer Cell Line | EDJ-KQ88 | Mouse | 52463 | Details Get a Quote |
| NR1H3 Knockout HEK293T Cell Line | EDJ-KQ109 | Human | 10062 | Details Get a Quote |
| NR1H2 Knockout HEK293T Cell Line | EDJ-KQ110 | Human | 7376 | Details Get a Quote |
| RPS6KB2 Knockout HEK293 Cell Line | EDJ-KQ125 | Human | 6199 | Details Get a Quote |
| SMAD6 Knockout HEK293 Cell Line | EDJ-KQ126 | Human | 4091 | Details Get a Quote |
| JUN Knockout HEK293 Cell Line | EDJ-KQ176 | Human | 3725 | Details Get a Quote |
| JUN Knockout HEK293T Cell Line | EDJ-KQ184 | Human | 3725 | Details Get a Quote |
| ALKBH5 Knockout HEK293 Cell Line | EDJ-KQ186 | Human | 54890 | Details Get a Quote |
- 1
- 2
- ...
- Next Page »